Artrya (ASX:AYA) Valuation Rank


ASX:AYA Artrya Ltd ASX:AYA
30 GF Score
Price A$6.10
! 1 Warning Sign
View Full Analysis

What is Artrya Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Artrya Valuation Rank Related Terms

ASX:AYA
30GF Score
Artrya Ltd ASX:AYA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artrya Business Description

Address 1257 Hay Street, West Perth, Perth, WA, AUS, 6005
Artrya Ltd is a medical technology company. The company is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. It is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.
30GF Score

Get the complete analysis for ASX:AYA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$6.10
Price